Zydus Focuses on M&A and Licensing to Develop US Specialty Business

Zydus Lifesciences is on a mission to strengthen its US specialty business through mergers, acquisitions, and licensing. The company is gearing up for the potential launch of its liver therapy drug, saroglitazar, in the US market. Additionally, Zydus is eyeing expansion into medical devices, diagnostics, and nutrition sectors to ensure profitable growth and innovation-driven approach by 2030.

In a recent interview, Sharvil Patel, the Managing Director of Zydus Lifesciences, shared insights into the company’s strategy. Patel highlighted the company’s success in the US generics market and reiterated the commitment to maintaining strong performance and profitability. With an extensive pipeline and exclusive launches planned, Zydus is set to introduce a range of new products to the market, including generic versions of popular drugs like Revlimid and Asacol HD.

When asked about their US plans for orphan and rare diseases, Patel emphasized the company’s dedication to building a specialty portfolio. Zydus aims to have commercially viable products ready to go, alongside the launch of saroglitazar. In the coming year, the company anticipates positive results for Saro, following which they may explore opportunities for licensing or acquisitions to expand their product offerings.

While Zydus has been perceived as less active in acquisitions compared to some competitors, Patel hinted at a shift in strategy. The company is leaning towards more overseas acquisitions, particularly in the US market. Patel mentioned a potential interest in the European market as well, given the attractive valuations and growth opportunities.

In conclusion, Zydus Lifesciences is poised for strategic growth through M&A, licensing, and diversification in the US specialty market. With a focus on innovation and profitability, the company is laying the groundwork for a successful future in the healthcare industry.